GI ASCO 2024 Highlights with Dr. Pamela Kunz - CheckMate 8HW, EMERALD-1, NETTER-2

[@NurburgringUP]

I certainly appreciate the effort that goes into this. Well selected studies, short and to the point discussion, thanks for your hard work. I do believe we should be more critical with the comparator arms in many of these trials, as no one in their right mind would give them to their father: Netter-2: Octreotide in a G3 neuroendocrine tumor with a Ki67 of 50% Checkmate 8HW: Folfox in MSI-H stage IV colon cancer Emerald: TACE alone in unresectable HCC Having a weak comparator arm is an easy way to show your drug is “better”. All of them border on unethical.